Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Apolipoprotein M and risk of type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{41c12bad0f5b4f05aa65f5391086a05d,
title = "Apolipoprotein M and risk of type 2 diabetes",
abstract = "CONTEXT: Recent studies have discovered a role of apolipoprotein M (apoM) in energy metabolism, and observational analyses in humans suggest an association with type 2 diabetes. The causal relationship remains however elusive.OBJECTIVE: To investigate whether reduced plasma apoM concentrations are causally linked to increased risk of type 2 diabetes.DESIGN: Prospective study design analyzed by Mendelian randomization.SETTING AND PARTICIPANTS: Two cohorts reflecting the Danish general population: the Copenhagen City Heart Study (CCHS, n = 8589) and the Copenhagen General Population Study (CGPS; n = 93 857). Observational analyses included a subset of participants from the CCHS with available plasma apoM (n = 725). Genetic analyses included the complete cohorts (n = 102 446). During a median follow-up of 16 years (CCHS) and 8 years (CGPS), 563 and 2132 participants developed type 2 diabetes.MAIN OUTCOME MEASURES: Plasma apoM concentration, genetic variants in APOM, and type 2 diabetes.RESULTS: First, we identified an inverse correlation between plasma apoM and risk of type 2 diabetes in a subset of participants from the CCHS (hazard ratio between highest vs lowest quartile (reference) = 0.32; 95{\%} confidence interval = 0.1-1.01; P for trend = .02). Second, genotyping of specific single nucleotide polymorphisms in APOM further revealed a 10.8{\%} (P = 6.2 × 10-5) reduced plasma apoM concentration in participants with variant rs1266078. Third, a meta-analysis including data from 599 451 individuals showed no association between rs1266078 and risk of type 2 diabetes.CONCLUSIONS: The present study does not appear to support a causal association between plasma apoM and risk of type 2 diabetes.",
author = "Stefan Hajny and Mette Christoffersen and Nawar Dalila and Nielsen, {Lars B} and Anne Tybj{\ae}rg-Hansen and Christina Christoffersen",
note = "{\circledC} Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",
year = "2020",
month = "9",
day = "1",
doi = "10.1210/clinem/dgaa433",
language = "English",
volume = "105",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The/Endocrine Society",
number = "9",

}

RIS

TY - JOUR

T1 - Apolipoprotein M and risk of type 2 diabetes

AU - Hajny, Stefan

AU - Christoffersen, Mette

AU - Dalila, Nawar

AU - Nielsen, Lars B

AU - Tybjærg-Hansen, Anne

AU - Christoffersen, Christina

N1 - © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - CONTEXT: Recent studies have discovered a role of apolipoprotein M (apoM) in energy metabolism, and observational analyses in humans suggest an association with type 2 diabetes. The causal relationship remains however elusive.OBJECTIVE: To investigate whether reduced plasma apoM concentrations are causally linked to increased risk of type 2 diabetes.DESIGN: Prospective study design analyzed by Mendelian randomization.SETTING AND PARTICIPANTS: Two cohorts reflecting the Danish general population: the Copenhagen City Heart Study (CCHS, n = 8589) and the Copenhagen General Population Study (CGPS; n = 93 857). Observational analyses included a subset of participants from the CCHS with available plasma apoM (n = 725). Genetic analyses included the complete cohorts (n = 102 446). During a median follow-up of 16 years (CCHS) and 8 years (CGPS), 563 and 2132 participants developed type 2 diabetes.MAIN OUTCOME MEASURES: Plasma apoM concentration, genetic variants in APOM, and type 2 diabetes.RESULTS: First, we identified an inverse correlation between plasma apoM and risk of type 2 diabetes in a subset of participants from the CCHS (hazard ratio between highest vs lowest quartile (reference) = 0.32; 95% confidence interval = 0.1-1.01; P for trend = .02). Second, genotyping of specific single nucleotide polymorphisms in APOM further revealed a 10.8% (P = 6.2 × 10-5) reduced plasma apoM concentration in participants with variant rs1266078. Third, a meta-analysis including data from 599 451 individuals showed no association between rs1266078 and risk of type 2 diabetes.CONCLUSIONS: The present study does not appear to support a causal association between plasma apoM and risk of type 2 diabetes.

AB - CONTEXT: Recent studies have discovered a role of apolipoprotein M (apoM) in energy metabolism, and observational analyses in humans suggest an association with type 2 diabetes. The causal relationship remains however elusive.OBJECTIVE: To investigate whether reduced plasma apoM concentrations are causally linked to increased risk of type 2 diabetes.DESIGN: Prospective study design analyzed by Mendelian randomization.SETTING AND PARTICIPANTS: Two cohorts reflecting the Danish general population: the Copenhagen City Heart Study (CCHS, n = 8589) and the Copenhagen General Population Study (CGPS; n = 93 857). Observational analyses included a subset of participants from the CCHS with available plasma apoM (n = 725). Genetic analyses included the complete cohorts (n = 102 446). During a median follow-up of 16 years (CCHS) and 8 years (CGPS), 563 and 2132 participants developed type 2 diabetes.MAIN OUTCOME MEASURES: Plasma apoM concentration, genetic variants in APOM, and type 2 diabetes.RESULTS: First, we identified an inverse correlation between plasma apoM and risk of type 2 diabetes in a subset of participants from the CCHS (hazard ratio between highest vs lowest quartile (reference) = 0.32; 95% confidence interval = 0.1-1.01; P for trend = .02). Second, genotyping of specific single nucleotide polymorphisms in APOM further revealed a 10.8% (P = 6.2 × 10-5) reduced plasma apoM concentration in participants with variant rs1266078. Third, a meta-analysis including data from 599 451 individuals showed no association between rs1266078 and risk of type 2 diabetes.CONCLUSIONS: The present study does not appear to support a causal association between plasma apoM and risk of type 2 diabetes.

U2 - 10.1210/clinem/dgaa433

DO - 10.1210/clinem/dgaa433

M3 - Journal article

VL - 105

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 9

M1 - dgaa433

ER -

ID: 60693244